JAK2 and COVID-19: An in vitro study by Wu and Yang, (2020) suggested the promising potential of selective JAK2 inhibitor fedratinib in suppressing TH17-associated cytokine production (IL-17, IL-22, GM-CSF) during the management of COVID-19 and other related viruses.